IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i4p2263-d751328.html
   My bibliography  Save this article

Seropositivity of SARS-CoV-2 in the Population of Kazakhstan: A Nationwide Laboratory-Based Surveillance

Author

Listed:
  • Yuliya Semenova

    (Department of Neurology, Ophthalmology and Otolaryngology, Semey Medical University, Semey 071400, Kazakhstan)

  • Zhanna Kalmatayeva

    (School of Medicine, Al-Farabi Kazakh National University, Almaty 050040, Kazakhstan)

  • Ainash Oshibayeva

    (Administrative Office, Khoja Akhmet Yassawi International Kazakh-Turkish University, Turkestan 161204, Kazakhstan)

  • Saltanat Mamyrbekova

    (School of Medicine, Al-Farabi Kazakh National University, Almaty 050040, Kazakhstan)

  • Aynura Kudirbekova

    (Invitro-Kazakhstan Laboratory, Medical Department, Almaty 050000, Kazakhstan)

  • Ardak Nurbakyt

    (Department of Public Health, Asfendiyarov Kazakh National Medical University, Almaty 050012, Kazakhstan)

  • Ardak Baizhaxynova

    (Department of Medicine, Nazarbayev University School of Medicine, Nur-Sultan 020000, Kazakhstan)

  • Paolo Colet

    (Department of Medicine, Nazarbayev University School of Medicine, Nur-Sultan 020000, Kazakhstan)

  • Natalya Glushkova

    (School of Medicine, Al-Farabi Kazakh National University, Almaty 050040, Kazakhstan)

  • Alexandr Ivankov

    (Independent Researcher, Almaty 050000, Kazakhstan)

  • Antonio Sarria-Santamera

    (Department of Medicine, Nazarbayev University School of Medicine, Nur-Sultan 020000, Kazakhstan)

Abstract

The data on seroprevalence of anti-SARS-CoV-2 antibodies in Kazakhstani population are non-existent, but are needed for planning of public health interventions targeted to COVID-19 containment. The aim of the study was to estimate the seropositivity of SARS-CoV-2 infection in the Kazakhstani population from 2020 to 2021. We relied on the data obtained from the results from “IN VITRO” laboratories of enzyme-linked immunosorbent assays for class G immunoglobulins (IgG) and class M (IgM) to SARS-CoV-2. The association of COVID-19 seropositivity was assessed in relation to age, gender, and region of residence. Additionally, we related the monitoring of longitudinal seropositivity with COVID-19 statistics obtained from Our World in Data. The total numbers of tests were 68,732 for SARS-CoV-2 IgM and 85,346 for IgG, of which 22% and 63% were positive, respectively. The highest rates of positive anti-SARS-CoV-2 IgM results were seen during July/August 2020. The rate of IgM seropositivity was the lowest on 25 October 2020 (2%). The lowest daily rate of anti-SARS-CoV-2 IgG was 17% (13 December 2020), while the peak of IgG seropositivity was seen on 6 June 2021 (84%). A longitudinal serological study should be envisaged to facilitate understanding of the dynamics of the epidemiological situation and to forecast future scenarios.

Suggested Citation

  • Yuliya Semenova & Zhanna Kalmatayeva & Ainash Oshibayeva & Saltanat Mamyrbekova & Aynura Kudirbekova & Ardak Nurbakyt & Ardak Baizhaxynova & Paolo Colet & Natalya Glushkova & Alexandr Ivankov & Antoni, 2022. "Seropositivity of SARS-CoV-2 in the Population of Kazakhstan: A Nationwide Laboratory-Based Surveillance," IJERPH, MDPI, vol. 19(4), pages 1-14, February.
    • Handle: RePEc:gam:jijerp:v:19:y:2022:i:4:p:2263-:d:751328
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/4/2263/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/19/4/2263/
    Download Restriction: no
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:4:p:2263-:d:751328. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.